Reinfarction after thrombölytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking

A group of 456 consecutive patients seen ≤ 6 h after the onset of acute myocardial infarction associated with ST segment elevation received thrombolytic therapy and were followed up for 12 months. Intravenous streptokinase was given to 315 patients and recombinant tissue-type plasminogen activator (...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 1990-08, Vol.16 (2), p.340-348
Hauptverfasser: Rivers, John T., White, Harvey D., Cross, David B., Williams, Barbara F., Norris, Robin M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 348
container_issue 2
container_start_page 340
container_title Journal of the American College of Cardiology
container_volume 16
creator Rivers, John T.
White, Harvey D.
Cross, David B.
Williams, Barbara F.
Norris, Robin M.
description A group of 456 consecutive patients seen ≤ 6 h after the onset of acute myocardial infarction associated with ST segment elevation received thrombolytic therapy and were followed up for 12 months. Intravenous streptokinase was given to 315 patients and recombinant tissue-type plasminogen activator (rt-PA) to 141 patients. Reinfarction rate and risk factors for reinfarction were assessed. Management after thrombolysis was conservative; revascularization procedures were reserved for patients with symptoms refractory to medical therapy or for those with left main coronary artery stenosis. Coronary artery surgery or angioplasty was performed in only 3.7% of patients during the first 30 days after thrombolysis and in only 8.6% by 1 year. Most patients (79%) underwent coronary arteriography. Twenty-six patients (5.7%) exhibited signs of threatened reinfarction at 1 month after thrombolytic therapy as did 43 patients (9.4%) by 1 year. Reinfarction was prevented in four of these patients by early readministration of thrombolytic therapy. Multivariate analysis of possible risk factors for reinfarction identified at the time of initial infaction showed current cigarette smoking to be the only predictive factor (reinfarction occurred in 12.5% of smokers versus 6.3% of nonsmokers, p = 0.04). A second analysis of risk factors identified 3 weeks after initial infarction, including the severity of residual stenosis at coronary arteriography and exercise test variables, again showed continued cigarette smoking to be the only factor predictive of reinfarction. Twenty percent of patients who continued to smoke developed reinfarction compared with 5.1% of those who stopped (p < 0.01). Conservative management after thrombolysis with streptokinase or rt-PA results in a reinfarction rate of 8.6% at 1 year. Cigarette smoking predisposes patients to reinfarction; cessation of smoking reduces the risk of reinfarction. The impact of threatened reinfarction can be limited by prompt readministration of thrombolytic therapy.
doi_str_mv 10.1016/0735-1097(90)90583-B
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79894476</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>073510979090583B</els_id><sourcerecordid>79894476</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-ce6bdadfeb8fbc2dec9b0f9eef937a0e47a3c333dab5d0deca09cf3e044d9bc43</originalsourceid><addsrcrecordid>eNp9kdFqFDEUhoNY6lp9A4XcKHoxmtnM7Ey8EGzRtlAQRK_DmZOTGp1Jtkl2ZR6ir-ML-GJm3aV65VU4nO__Cd9h7EktXtWiXr0WnWyrWqjuhRIvlWh7WZ3eY4u6bftKtqq7zxZ3yAP2MKVvQohVX6tjdrysCyb7Bbv9RM5biJhd8Bxspsjz1xim4dfPcc4Oy0QR1jO3IXLATSY-zQEhGgcj_ydrwziGH2T4MHMMPlHcQnbbgoOHa5rI5zf80qMz5JE4eMPJWsLMg-VpCt-dv37EjiyMiR4f3hP25cP7z2cX1dXH88uzd1cVNn2XK6TVYMBYGno74NIQqkFYRWSV7EBQ04FEKaWBoTWirEEotJJE0xg1YCNP2PN97zqGmw2lrCeXkMYRPIVN0p3qVdN0qwI2exBjSCmS1evoJoizroXeXUHvFOudYq2E_nMFfVpiTw_9m2Eicxc6aC_7Z4c9JITRRihe0t9uJWXTL5eFe7vnqMjYOoo6odvpMy4Wc9oE9_-P_AZEx6pW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79894476</pqid></control><display><type>article</type><title>Reinfarction after thrombölytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Rivers, John T. ; White, Harvey D. ; Cross, David B. ; Williams, Barbara F. ; Norris, Robin M.</creator><creatorcontrib>Rivers, John T. ; White, Harvey D. ; Cross, David B. ; Williams, Barbara F. ; Norris, Robin M.</creatorcontrib><description>A group of 456 consecutive patients seen ≤ 6 h after the onset of acute myocardial infarction associated with ST segment elevation received thrombolytic therapy and were followed up for 12 months. Intravenous streptokinase was given to 315 patients and recombinant tissue-type plasminogen activator (rt-PA) to 141 patients. Reinfarction rate and risk factors for reinfarction were assessed. Management after thrombolysis was conservative; revascularization procedures were reserved for patients with symptoms refractory to medical therapy or for those with left main coronary artery stenosis. Coronary artery surgery or angioplasty was performed in only 3.7% of patients during the first 30 days after thrombolysis and in only 8.6% by 1 year. Most patients (79%) underwent coronary arteriography. Twenty-six patients (5.7%) exhibited signs of threatened reinfarction at 1 month after thrombolytic therapy as did 43 patients (9.4%) by 1 year. Reinfarction was prevented in four of these patients by early readministration of thrombolytic therapy. Multivariate analysis of possible risk factors for reinfarction identified at the time of initial infaction showed current cigarette smoking to be the only predictive factor (reinfarction occurred in 12.5% of smokers versus 6.3% of nonsmokers, p = 0.04). A second analysis of risk factors identified 3 weeks after initial infarction, including the severity of residual stenosis at coronary arteriography and exercise test variables, again showed continued cigarette smoking to be the only factor predictive of reinfarction. Twenty percent of patients who continued to smoke developed reinfarction compared with 5.1% of those who stopped (p &lt; 0.01). Conservative management after thrombolysis with streptokinase or rt-PA results in a reinfarction rate of 8.6% at 1 year. Cigarette smoking predisposes patients to reinfarction; cessation of smoking reduces the risk of reinfarction. The impact of threatened reinfarction can be limited by prompt readministration of thrombolytic therapy.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/0735-1097(90)90583-B</identifier><identifier>PMID: 2115538</identifier><identifier>CODEN: JACCDI</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Cardiac Catheterization ; Combined Modality Therapy ; Coronary Angiography ; Coronary Artery Bypass ; Creatine Kinase - blood ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Myocardial Infarction - mortality ; Myocardial Infarction - physiopathology ; Myocardial Infarction - therapy ; Pharmacology. Drug treatments ; Randomized Controlled Trials as Topic ; Recombinant Proteins - therapeutic use ; Recurrence ; Risk Factors ; Smoking - adverse effects ; Smoking - epidemiology ; Streptokinase - therapeutic use ; Survival Rate ; Thrombolytic Therapy ; Tissue Plasminogen Activator - therapeutic use</subject><ispartof>Journal of the American College of Cardiology, 1990-08, Vol.16 (2), p.340-348</ispartof><rights>1990</rights><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-ce6bdadfeb8fbc2dec9b0f9eef937a0e47a3c333dab5d0deca09cf3e044d9bc43</citedby><cites>FETCH-LOGICAL-c487t-ce6bdadfeb8fbc2dec9b0f9eef937a0e47a3c333dab5d0deca09cf3e044d9bc43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0735-1097(90)90583-B$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=19334822$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2115538$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rivers, John T.</creatorcontrib><creatorcontrib>White, Harvey D.</creatorcontrib><creatorcontrib>Cross, David B.</creatorcontrib><creatorcontrib>Williams, Barbara F.</creatorcontrib><creatorcontrib>Norris, Robin M.</creatorcontrib><title>Reinfarction after thrombölytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking</title><title>Journal of the American College of Cardiology</title><addtitle>J Am Coll Cardiol</addtitle><description>A group of 456 consecutive patients seen ≤ 6 h after the onset of acute myocardial infarction associated with ST segment elevation received thrombolytic therapy and were followed up for 12 months. Intravenous streptokinase was given to 315 patients and recombinant tissue-type plasminogen activator (rt-PA) to 141 patients. Reinfarction rate and risk factors for reinfarction were assessed. Management after thrombolysis was conservative; revascularization procedures were reserved for patients with symptoms refractory to medical therapy or for those with left main coronary artery stenosis. Coronary artery surgery or angioplasty was performed in only 3.7% of patients during the first 30 days after thrombolysis and in only 8.6% by 1 year. Most patients (79%) underwent coronary arteriography. Twenty-six patients (5.7%) exhibited signs of threatened reinfarction at 1 month after thrombolytic therapy as did 43 patients (9.4%) by 1 year. Reinfarction was prevented in four of these patients by early readministration of thrombolytic therapy. Multivariate analysis of possible risk factors for reinfarction identified at the time of initial infaction showed current cigarette smoking to be the only predictive factor (reinfarction occurred in 12.5% of smokers versus 6.3% of nonsmokers, p = 0.04). A second analysis of risk factors identified 3 weeks after initial infarction, including the severity of residual stenosis at coronary arteriography and exercise test variables, again showed continued cigarette smoking to be the only factor predictive of reinfarction. Twenty percent of patients who continued to smoke developed reinfarction compared with 5.1% of those who stopped (p &lt; 0.01). Conservative management after thrombolysis with streptokinase or rt-PA results in a reinfarction rate of 8.6% at 1 year. Cigarette smoking predisposes patients to reinfarction; cessation of smoking reduces the risk of reinfarction. The impact of threatened reinfarction can be limited by prompt readministration of thrombolytic therapy.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Cardiac Catheterization</subject><subject>Combined Modality Therapy</subject><subject>Coronary Angiography</subject><subject>Coronary Artery Bypass</subject><subject>Creatine Kinase - blood</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Myocardial Infarction - mortality</subject><subject>Myocardial Infarction - physiopathology</subject><subject>Myocardial Infarction - therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Recurrence</subject><subject>Risk Factors</subject><subject>Smoking - adverse effects</subject><subject>Smoking - epidemiology</subject><subject>Streptokinase - therapeutic use</subject><subject>Survival Rate</subject><subject>Thrombolytic Therapy</subject><subject>Tissue Plasminogen Activator - therapeutic use</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kdFqFDEUhoNY6lp9A4XcKHoxmtnM7Ey8EGzRtlAQRK_DmZOTGp1Jtkl2ZR6ir-ML-GJm3aV65VU4nO__Cd9h7EktXtWiXr0WnWyrWqjuhRIvlWh7WZ3eY4u6bftKtqq7zxZ3yAP2MKVvQohVX6tjdrysCyb7Bbv9RM5biJhd8Bxspsjz1xim4dfPcc4Oy0QR1jO3IXLATSY-zQEhGgcj_ydrwziGH2T4MHMMPlHcQnbbgoOHa5rI5zf80qMz5JE4eMPJWsLMg-VpCt-dv37EjiyMiR4f3hP25cP7z2cX1dXH88uzd1cVNn2XK6TVYMBYGno74NIQqkFYRWSV7EBQ04FEKaWBoTWirEEotJJE0xg1YCNP2PN97zqGmw2lrCeXkMYRPIVN0p3qVdN0qwI2exBjSCmS1evoJoizroXeXUHvFOudYq2E_nMFfVpiTw_9m2Eicxc6aC_7Z4c9JITRRihe0t9uJWXTL5eFe7vnqMjYOoo6odvpMy4Wc9oE9_-P_AZEx6pW</recordid><startdate>19900801</startdate><enddate>19900801</enddate><creator>Rivers, John T.</creator><creator>White, Harvey D.</creator><creator>Cross, David B.</creator><creator>Williams, Barbara F.</creator><creator>Norris, Robin M.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19900801</creationdate><title>Reinfarction after thrombölytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking</title><author>Rivers, John T. ; White, Harvey D. ; Cross, David B. ; Williams, Barbara F. ; Norris, Robin M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-ce6bdadfeb8fbc2dec9b0f9eef937a0e47a3c333dab5d0deca09cf3e044d9bc43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Cardiac Catheterization</topic><topic>Combined Modality Therapy</topic><topic>Coronary Angiography</topic><topic>Coronary Artery Bypass</topic><topic>Creatine Kinase - blood</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Myocardial Infarction - mortality</topic><topic>Myocardial Infarction - physiopathology</topic><topic>Myocardial Infarction - therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Recurrence</topic><topic>Risk Factors</topic><topic>Smoking - adverse effects</topic><topic>Smoking - epidemiology</topic><topic>Streptokinase - therapeutic use</topic><topic>Survival Rate</topic><topic>Thrombolytic Therapy</topic><topic>Tissue Plasminogen Activator - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rivers, John T.</creatorcontrib><creatorcontrib>White, Harvey D.</creatorcontrib><creatorcontrib>Cross, David B.</creatorcontrib><creatorcontrib>Williams, Barbara F.</creatorcontrib><creatorcontrib>Norris, Robin M.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rivers, John T.</au><au>White, Harvey D.</au><au>Cross, David B.</au><au>Williams, Barbara F.</au><au>Norris, Robin M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reinfarction after thrombölytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking</atitle><jtitle>Journal of the American College of Cardiology</jtitle><addtitle>J Am Coll Cardiol</addtitle><date>1990-08-01</date><risdate>1990</risdate><volume>16</volume><issue>2</issue><spage>340</spage><epage>348</epage><pages>340-348</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><coden>JACCDI</coden><abstract>A group of 456 consecutive patients seen ≤ 6 h after the onset of acute myocardial infarction associated with ST segment elevation received thrombolytic therapy and were followed up for 12 months. Intravenous streptokinase was given to 315 patients and recombinant tissue-type plasminogen activator (rt-PA) to 141 patients. Reinfarction rate and risk factors for reinfarction were assessed. Management after thrombolysis was conservative; revascularization procedures were reserved for patients with symptoms refractory to medical therapy or for those with left main coronary artery stenosis. Coronary artery surgery or angioplasty was performed in only 3.7% of patients during the first 30 days after thrombolysis and in only 8.6% by 1 year. Most patients (79%) underwent coronary arteriography. Twenty-six patients (5.7%) exhibited signs of threatened reinfarction at 1 month after thrombolytic therapy as did 43 patients (9.4%) by 1 year. Reinfarction was prevented in four of these patients by early readministration of thrombolytic therapy. Multivariate analysis of possible risk factors for reinfarction identified at the time of initial infaction showed current cigarette smoking to be the only predictive factor (reinfarction occurred in 12.5% of smokers versus 6.3% of nonsmokers, p = 0.04). A second analysis of risk factors identified 3 weeks after initial infarction, including the severity of residual stenosis at coronary arteriography and exercise test variables, again showed continued cigarette smoking to be the only factor predictive of reinfarction. Twenty percent of patients who continued to smoke developed reinfarction compared with 5.1% of those who stopped (p &lt; 0.01). Conservative management after thrombolysis with streptokinase or rt-PA results in a reinfarction rate of 8.6% at 1 year. Cigarette smoking predisposes patients to reinfarction; cessation of smoking reduces the risk of reinfarction. The impact of threatened reinfarction can be limited by prompt readministration of thrombolytic therapy.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>2115538</pmid><doi>10.1016/0735-1097(90)90583-B</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0735-1097
ispartof Journal of the American College of Cardiology, 1990-08, Vol.16 (2), p.340-348
issn 0735-1097
1558-3597
language eng
recordid cdi_proquest_miscellaneous_79894476
source MEDLINE; Elsevier ScienceDirect Journals Complete; EZB-FREE-00999 freely available EZB journals
subjects Aged
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Cardiac Catheterization
Combined Modality Therapy
Coronary Angiography
Coronary Artery Bypass
Creatine Kinase - blood
Female
Humans
Male
Medical sciences
Middle Aged
Multivariate Analysis
Myocardial Infarction - mortality
Myocardial Infarction - physiopathology
Myocardial Infarction - therapy
Pharmacology. Drug treatments
Randomized Controlled Trials as Topic
Recombinant Proteins - therapeutic use
Recurrence
Risk Factors
Smoking - adverse effects
Smoking - epidemiology
Streptokinase - therapeutic use
Survival Rate
Thrombolytic Therapy
Tissue Plasminogen Activator - therapeutic use
title Reinfarction after thrombölytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T03%3A57%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reinfarction%20after%20thromb%C3%B6lytic%20therapy%20for%20acute%20myocardial%20infarction%20followed%20by%20conservative%20management:%20Incidence%20and%20effect%20of%20smoking&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Rivers,%20John%20T.&rft.date=1990-08-01&rft.volume=16&rft.issue=2&rft.spage=340&rft.epage=348&rft.pages=340-348&rft.issn=0735-1097&rft.eissn=1558-3597&rft.coden=JACCDI&rft_id=info:doi/10.1016/0735-1097(90)90583-B&rft_dat=%3Cproquest_cross%3E79894476%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79894476&rft_id=info:pmid/2115538&rft_els_id=073510979090583B&rfr_iscdi=true